Abstract
Sonodynamically induced antitumor effect of a gallium porphyrin complex, ATX-70 was evaluated on a chemically induced mammary tumor in Sprague-Dawley rats. The timing of 24 h after the administration of ATX-70 was chosen for ultrasonic exposure, based on pharmacokinetic analysis of ATX-70 concentrations in the tumor, plasma, skin, and muscle. At an ATX-70 dose not less than 2.5 mg/kg and at a free-field ultrasonic intensity not less than 3 W/cm(2), the synergistic effect between ATX-70 administration and ultrasonic exposure on the tumor growth inhibition was significant. These results suggest that ATX-70 is a potential sonosensitizer for sonodynamic treatment of spontaneous mammary tumors.
MeSH terms
-
9,10-Dimethyl-1,2-benzanthracene
-
Animals
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / pharmacokinetics
-
Antineoplastic Agents / pharmacology*
-
Area Under Curve
-
Combined Modality Therapy
-
Drug Screening Assays, Antitumor
-
Female
-
Mammary Neoplasms, Experimental / chemically induced
-
Mammary Neoplasms, Experimental / therapy*
-
Photosensitizing Agents / administration & dosage
-
Photosensitizing Agents / pharmacokinetics
-
Photosensitizing Agents / pharmacology*
-
Porphyrins / administration & dosage
-
Porphyrins / pharmacokinetics
-
Porphyrins / pharmacology*
-
Rats
-
Rats, Sprague-Dawley
-
Time Factors
-
Tissue Distribution
-
Ultrasonic Therapy*
Substances
-
Antineoplastic Agents
-
Photosensitizing Agents
-
Porphyrins
-
ATX 70
-
9,10-Dimethyl-1,2-benzanthracene